Alopecia Areata: Review of Epidemiology, Pathophysiology, Current Treatments and Nanoparticulate Delivery System

This study explored the development of polymeric nanoparticles for topical spironolactone delivery, finding that larger nanoparticles (180 nm) enhanced drug targeting to hair follicles significantly more than smaller ones or non-nanoparticle formulations, offering promise for safer acne and alopecia treatments.

This study found that excipients significantly influence the effectiveness of curcumin nanocrystals in dermal applications, enhancing or hindering hair follicle targeting and passive diffusion based on their selection.

This study found that finasteride- and dutasteride-loaded iron oxide nanoparticles improved drug penetration in the skin, suggesting they may be promising for topical alopecia therapies.

This study found that nanostructured lipid carriers with clobetasol propionate significantly enhance follicular drug delivery compared to commercial cream, and manual massage further doubles follicular retention.

This study investigated the use of Minoxidil encapsulated in HA-PLGA nanoparticles for alopecia treatment and found that these nanoparticles efficiently delivered the drug to hair follicle cells without significant cytotoxicity, offering a potential transdermal delivery method for various diseases.

This study found that minoxidil nanoparticles increased drug delivery to hair follicles and improved hair growth more effectively in mice than conventional minoxidil formulations.

This review article provides an updated overview of the pharmacology, mechanism of action, clinical efficacy, and adverse events associated with topical minoxidil, a widely used treatment for androgenetic alopecia and other hair loss conditions, while noting that its exact mechanism is still not fully understood.

This study reviewed recent theories on alopecia areata's pathogenesis, highlighting its autoimmune nature due to immune privilege disruption in hair follicles, and noted current treatments have limited efficacy with high relapse rates, underscoring the need for further research into its mechanisms for better therapies.

This study found that transverse sections of scalp biopsies, particularly looking at the anagen:non-anagen hair ratio and presence of pigment casts, effectively distinguish alopecia areata from androgenetic alopecia.

This review examines the literature on autoimmune hair loss disorders, highlighting the collapse of immune privilege and the potential role of neurogenic stress in this process, but reports no new clinical results.

This review examines the potential of bimatoprost for treating various types of eyelash and eyebrow hypotrichosis, discussing its pharmacological properties but providing no new clinical results.

This case study describes severe hypertrichosis in a 3-year-old with alopecia areata after unsupervised use of high-dose topical minoxidil, highlighting the need to avoid such practices in children.

This study found that polymeric nanoparticles may effectively deliver finasteride topically to hair follicles, potentially improving alopecia treatment with fewer side effects than oral forms.

This study observed that autologous bone marrow derived mononuclear cells and follicular stem cells were both safe and effective for improving resistant alopecia areata and androgenetic alopecia, with no serious adverse events.

This study found that nanostructured lipid carriers enhanced the skin penetration and retention of minoxidil compared to solid lipid nanoparticles, suggesting they could be a promising method for topical delivery.

This review discusses the potential of follicular drug delivery systems to target the pilosebaceous unit and reports no new research findings.

This study found that nanocapsules formulated as a dispersion and applied with massage may enhance follicular uptake of clobetasol propionate while minimizing its skin penetration, offering a potential improvement over conventional treatments for scalp diseases.

Tiny particles carrying roxithromycin can effectively target and deliver the drug to hair follicles without irritation.

This article discusses the social and psychological impact of hair disorders and the challenges in their treatment, but reports no new clinical results.

This study concluded that Flutamide-loaded solid lipid nanoparticles may enhance hair follicle drug delivery and promote hair growth in androgenic alopecia compared to a Flutamide hydroalcoholic solution.

This review reports that alopecia areata affects about 2% of people globally and is linked with psychiatric and medical comorbidities, highlighting its significant disease burden.

This study developed minoxidil sulphate-loaded chitosan nanoparticles that doubled drug delivery to hair follicles in vitro compared to a control solution, suggesting potential for improved alopecia treatment.

This paper reviews current treatments for alopecia areata and emphasizes the importance of tailoring therapy to each patient's specific condition and needs without reporting new clinical results.

This research reported that squarticles, nanoparticles made from sebum-derived lipids, enhanced the follicular delivery and skin accumulation of diphencyprone and minoxidil, indicating effective drug deposition with reduced systemic absorption in alopecia treatment.

This study found that topical clobetasol propionate cream was more effective than hydrocortisone cream in reducing hair loss surface area in children with patchy alopecia areata over 24 weeks, with no serious adverse effects.

This study found that nanostructured lipid carriers with more soybean phosphatidylcholine provided better skin retention and follicular targeting for diphencyprone compared to other formulations and controls.

Nanoparticles can be used to deliver drugs to hair follicles, potentially improving treatments for conditions like acne and alopecia, and could also be used for vaccine delivery and gene therapy.

This review discusses recent advances in skin penetration mechanisms, specifically focusing on the enhanced understanding of the follicular pathway and its implications for transdermal therapies, immune system targeting, and nanoparticle safety.

Alopecia Areata is an autoimmune condition causing hair loss with no cure and treatments that often don't work well.

The human hair follicle can store topical compounds and be targeted for drug delivery with minimal side effects.

This study found that topical pimecrolimus is as effective as clobetasol propionate for treating alopecia areata, with better tolerability in terms of side effects.

This review discusses various therapeutic agents for alopecia areata, categorized by efficacy and safety, and highlights the lack of curative treatments and long-term outcome studies.

This study found that solid lipid nanoparticles with minoxidil were as effective as commercial solutions for skin penetration and were non-corrosive, indicating potential for hair loss treatment.

This review discusses potential new drug treatment strategies for alopecia areata based on genome-wide association study findings, but it reports no new clinical results.

This study in Japan found varying prevalence of skin disorders, with atopic dermatitis common in children and tinea pedis in the elderly, and observed gender differences in disease susceptibility.

This review examines topical immunotherapy for severe alopecia areata, noting that diphencyprone and squaric acid dibutylester are non-mutagenic options with similar efficacy but different practical considerations, and reports no new clinical results.

This study found that latanoprost may be effective for treating eyelash alopecia areata, achieving cosmetically acceptable regrowth in 45% of patients.

This study found that the 308-nm Excimer laser was effective and safe for treating patchy alopecia areata in children, with hair regrowth observed in 60% of treated scalp patches.

This study found that a regimen of oral prednisolone followed by topical minoxidil showed promise as a noninvasive treatment for alopecia areata, suggesting potential benefits for hair regrowth and prevention of hair loss.

This study identified four genetic loci on chromosomes 6, 10, 16, and 18 that may contribute to susceptibility for alopecia areata and suggested shared genetic factors with psoriasis.

This study found that liposomal formulations improved minoxidil delivery to skin layers compared to niosomes and a control solution, suggesting enhanced potential for topical hair loss treatment.

In this study, clobetasol propionate foam demonstrated effectiveness and good patient compliance as a safe topical treatment for moderate to severe alopecia areata, with significant hair regrowth compared to placebo.

This study found that intramuscular triamcinolone acetonide or pulse therapy effectively treats alopecia areata with manageable side effects, but further strategies are needed to reduce relapse rates.

In this study, oral prednisolone pulse therapy led to significant hair regrowth in some patients with extensive alopecia areata, whereas no improvement was seen in the placebo group.

In this study, researchers found that in hairy guinea pig skin, minoxidil delivered via 40-nm nanoparticles had higher skin penetration than 130-nm nanoparticles, indicating nanoparticle size affects permeation.

This study found that using a standardized protocol with microspheres of approximately 1.5 micrometers enhances penetration into hair follicles, particularly when skin is treated with cyanoacrylate skin surface stripping.

In this 48-week trial, 5% topical minoxidil was more effective than both 2% minoxidil and placebo in promoting hair growth in women with female pattern hair loss, with notable improvements in nonvellus hair count and hair growth assessments.

In this study, clobetasol propionate 0.05% ointment was found to induce hair regrowth in 28.5% of patients with severe alopecia areata under occlusive conditions, though long-term benefit was limited to 17.8%.

Stress can cause hair loss and skin issues by affecting hair growth cycles.

Minoxidil can cause skin allergy; use alternative solvents or treatments if allergic.

This report observed that a male developed erythema multiforme linked to both topical and oral minoxidil use for androgenetic alopecia, supported by eruption recurrence with reapplication.

In this study, tapering prednisone followed by 2% topical minoxidil helped limit hair loss in some patients with alopecia areata, with 30% to 47% showing over 25% hair regrowth initially.

Minoxidil doesn't affect perifollicular lymphoid infiltration in alopecia areata patients.

In this study, 0.5%-1.0% anthralin cream led to a cosmetic response in 25% of patients with severe alopecia areata, despite common side effects like pruritus and erythema.

This study found that oral minoxidil showed limited cosmetic effectiveness in treating severe alopecia areata, with only 18% of patients experiencing a noticeable response.

Minoxidil helps hair growth in 63.6% of alopecia patients, with 27.3% having excellent results.

In this study, 3% topical minoxidil showed some efficacy in hair regrowth for patients with extensive alopecia areata, especially those with less than total scalp hair loss, but did not lead to complete remission.

This study reports that topical minoxidil led to normalization of hair follicle characteristics in 36 of 47 severe alopecia areata patients, and indicated a shift in T cell populations, suggesting potential immunomodulatory effects.

This report discusses the potential of minoxidil for treating hair loss, spurred by early findings of hair regrowth in some patients, but emphasizes the need for further research to establish its safety and efficacy.